Tissue Regenix Group PLC Change of Adviser (2885Q)
18 February 2019 - 6:01PM
UK Regulatory
TIDMTRX
RNS Number : 2885Q
Tissue Regenix Group PLC
18 February 2019
Tissue Regenix Group plc
Change of Adviser
Leeds, 18 February 2019 - Tissue Regenix Group (AIM: TRX)
("Tissue Regenix" or the "Company") the regenerative medical
devices company, today announces the appointment of Stifel Nicolaus
Europe Limited as Nominated Adviser and Broker to the Company, with
immediate effect.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson, Head of Communications 07920 272441
--------------------------------------------- -------------------------
Stifel Nicolaus Europe Limited (Nominated Tel: +44 (0)20 7710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- -------------------------
FTI Consulting Tel: +44 (0)203 727 1000
Brett Pollard / Victoria Foster Mitchell
/ Mary Whittow
============================================= =========================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R)') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPMMGMZMNDGLZZ
(END) Dow Jones Newswires
February 18, 2019 02:01 ET (07:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024